BioNTech-Chef Ugur Sahin zeigt sich von dem Tempo der Mutationen beim Corona-Virus überrascht.
REUTERS
FILE PHOTO: CEO and co-founder of BioNTech, Ugur Sahin, answers journalists' questions after the European Medicines Agency (EMA) approved its COVID-19 vaccine, at the company headquarters in Mainz, Germany December 22, 2020. REUTERS/Ralph Orlowski/File Photo
Jetzt E-Paper lesen